Beta%252525252525252525252525252525252525252520blockers

# Beta Blockers ## Overview Beta-adrenergic blocking agents competitively antagonize catecholamine binding to beta-adrenergic receptors. They are categorized as non-selective (e.g., propranolol), cardioselective (beta-1 selective; e.g., metoprolol, atenolol, bisoprolol), or those with additional alpha-blocking/vasodilatory properties (e.g., carvedilol, nebivolol). ## Primary Indications * Hypertension * Chronic heart failure (HFrEF; specifically carvedilol, metoprolol succinate, bisoprolol) * Angina pectoris * Post-myocardial infarction * Atrial fibrillation/flutter (rate control) * Migraine prophylaxis (propranolol) * Essential tremor (propranolol) ## Adult Dosing * **Metoprolol Succinate (ER):** Start 25–50 mg daily; titrate to max 200 mg/day. * **Atenolol:** 25–50 mg daily; titrate to max 100 mg/day. * **Bisoprolol:** 2.5–5 mg daily; titrate to max 10 mg/day. * **Carvedilol (IR):** 3.125 mg twice daily; titrate to max 25 mg twice daily (HF), or 50 mg twice daily (HTN). * **Propranolol (Immediate Release):** 40 mg twice daily; range 80–320 mg/day. * *Note: Dosing is highly indication-specific; consult institutional guidelines for acute vs. chronic management.* ## Pediatric Dosing * **Propranolol:** 0.5–1 mg/kg/day divided twice daily; titrate based on response. * **Atenolol:** 0.5–1 mg/kg/day once daily. * **Metoprolol Tartrate:** 1–2 mg/kg/day divided twice daily. * *Note: Pediatric dosing is frequently off-label and varies significantly by indication (e.g., cardiac arrhythmias vs. hyperthyroidism); always use weight-based calculations and verify with neonatal/pediatric references.* ## Dose Adjustments * **Renal Impairment:** Atenolol and bisoprolol require dosage reduction in severe renal impairment (CrCl <30 mL/min). Metoprolol and carvedilol are primarily hepatically metabolized and generally do not require adjustment. * **Hepatic Impairment:** Reduce starting doses for propranolol and carvedilol due to extensive first-pass metabolism. ## Contraindications * Second or third-degree heart block (without a pacemaker). * Severe bradycardia (typically <50 bpm) or sick sinus syndrome. * Decompensated heart failure. * Severe reactive airway disease (asthma/COPD) for non-selective agents. * Cardiogenic shock. ## Adverse Effects * **Common:** Bradycardia, hypotension, fatigue, dizziness, sexual dysfunction. * **Metabolic:** Masking of hypoglycemic symptoms (except sweating) in diabetics; potential lipid profile changes. * **Respiratory:** Bronchospasm (non-selective). * **Psychiatric:** Depression, insomnia. ## Key Drug Interactions * **CYP2D6 Inhibitors (e.g., paroxetine, fluoxetine):** May significantly increase levels of carvedilol and metoprolol. * **Non-DHP Calcium Channel Blockers (verapamil, diltiazem):** Increases risk of severe bradycardia and heart block. * **Digoxin:** Additive effect on slowing AV node conduction. * **Insulin/Sulfonylureas:** Beta-blockers may blunt tachycardia as an early warning sign of hypoglycemia. ## Monitoring * Heart rate (target usually 55–70 bpm in chronic HF). * Blood pressure. * Signs/symptoms of heart failure exacerbation (weight gain, edema, dyspnea). * Blood glucose in patients with diabetes. * Renal/hepatic function labs as clinically indicated. ## Clinical Pearls * **Do not discontinue abruptly:** Must taper over 1–2 weeks to prevent "rebound" tachycardia and worsening angina/MI. * **Cardioselective agents (B1-selective):** Preferred in patients with mild-to-moderate pulmonary disease, though caution remains mandatory. * **Metoprolol Succinate vs. Tartrate:** These are not interchangeable; Succinate is indicated for extended-release once-daily dosing. * **Carvedilol:** Take with food to minimize orthostatic hypotension and improve tolerability. *** **Educational Disclaimer:** This information is for educational purposes only. Drug dosing, contraindications, and clinical practices may vary by local protocol and patient-specific factors. Always consult the most current product labeling (FDA/EMA) and official clinical practice guidelines before prescribing or administering medication.